Samalin L, Guillaume S, Courtet P, Abbar M, Lancrenon S, Llorca P-M
EA 7280, Psychiatrie d'adulte B, CHU de Clermont-Ferrand, université d'Auvergne, 63000 Clermont-Ferrand, France; Association française de psychiatrie biologique et neuropsychopharmacologie (AFPBN), centre hospitalier Sainte-Anne, 75674 Paris, France.
Association française de psychiatrie biologique et neuropsychopharmacologie (AFPBN), centre hospitalier Sainte-Anne, 75674 Paris, France; Inserm U1061, CHU de Montpellier, université de Montpellier, 34000 Montpellier, France.
Encephale. 2015 Feb;41(1):93-102. doi: 10.1016/j.encep.2014.11.002. Epub 2014 Dec 26.
As part of a process to improve the quality of care, the French Society for Biological Psychiatry and Neuropsychopharmacology developed in 2010 formal consensus guidelines for the treatment of bipolar disorder. The evolution of therapeutic options available in France for the treatment of bipolar disorder has justified the update of this guideline. The purpose of this work was to provide an updated and ergonomic document to promote its use by clinicians. This update focuses on two of the six thematic previously published (acute treatment and long-term treatment). Aspects of the treatment of bipolar patients sparking debate and questions of clinicians (use of antidepressant, place of the bitherapy, interest of long-acting antipsychotics…) were also covered. Finally, we proposed graded recommendations taking into account specifically the risk-benefit balance of each molecule.
作为提高医疗质量进程的一部分,法国生物精神病学与神经精神药理学协会于2010年制定了双相情感障碍治疗的正式共识指南。法国双相情感障碍治疗可用疗法的演变证明了该指南更新的合理性。这项工作的目的是提供一份更新且实用的文件,以促进临床医生使用。此次更新聚焦于先前发布的六个主题中的两个(急性治疗和长期治疗)。双相情感障碍患者治疗中引发临床医生辩论和疑问的方面(抗抑郁药的使用、联合治疗的地位、长效抗精神病药物的益处……)也涵盖在内。最后,我们提出了分级推荐,特别考虑了每种药物的风险效益平衡。